Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Massachusetts General Hospital |
---|---|
Information provided by: | Massachusetts General Hospital |
ClinicalTrials.gov Identifier: | NCT00455715 |
The study is a double-blind, placebo-controlled, random-order, single-dose crossover trial of sildenafil 50 & 100 mg added to stable antipsychotic treatment in schizophrenia patients to assess whether this PDE5 inhibitor improves cognitive functioning (including verbal memory, fluency, attention, spatial memory, motor speed, and executive function) and clinical symptoms (psychotic, negative, mood symptoms, and self-reports of side-effects).
Condition | Intervention | Phase |
---|---|---|
Schizophrenia |
Drug: Sildenafil |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Dose Comparison, Crossover Assignment, Safety/Efficacy Study |
Official Title: | A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia |
Enrollment: | 18 |
Study Start Date: | February 2006 |
Study Completion Date: | September 2007 |
Specific Aims:
Location and Subjects:
25 adult outpatients with schizophrenia will be recruited from the Massachusetts General Hospital outpatient clinic or the Freedom Trail Clinic of the Lindemann Center. All research procedures will be performed at the Psychopharmacology Clinic of the Massachusetts General Hospital. Subjects must be English speaking because the cognitive battery has only been validated in English.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 |
Principal Investigator: | Donald C Goff, M.D. | Massachusetts General Hospital |
Responsible Party: | Massachusetts General Hospital ( Donald Goff, MD ) |
Study ID Numbers: | 2005-P-000529 |
Study First Received: | April 2, 2007 |
Last Updated: | December 14, 2007 |
ClinicalTrials.gov Identifier: | NCT00455715 |
Health Authority: | United States: Institutional Review Board |
Schizophrenia Cognition Sildenafil PDE5 Inhibitor |
Schizophrenia Mental Disorders Sildenafil Psychotic Disorders Schizophrenia and Disorders with Psychotic Features |
Vasodilator Agents Phosphodiesterase Inhibitors Molecular Mechanisms of Pharmacological Action Therapeutic Uses |
Enzyme Inhibitors Cardiovascular Agents Pharmacologic Actions |